Conference/Events
|
42nd Annual Institutional… 42nd Annual Institutional Investors Virtual Conference will be held on March 1-3. ShowHide Related Items >><< - 02/25/21
- Weyerhaeuser to acquire Timberlands in Southwest Alabama from Greif
- 02/17/21
- Weyerhaeuser names Nancy Loewe as CFO, effective March 8
- 01/25/21
- Weyerhaeuser to recognize $253M pension settlement charge in Q4
- 10/30/20
- Weyerhaeuser reinitiates quarterly cash dividend
- 02/10/21
- ViaSat, GSS and TMC enter MOU to advance IFC services in Russia
- 02/09/21
- ViaSat awarded $8.5M contract to upgrade UHF SATCOM from Airbus
- 01/05/21
- Delta Air Lines selects ViaSat's Ka-band satellite IFC system
- 12/21/20
- ViaSat to acquire RigNet in $222M all-stock transaction
- 02/16/21
- Holders of 1.7M AeroGrow shares reject Scotts Miracle-Gro's $3 per share offer
- 02/03/21
- Scotts Miracle-Gro CEO says 'getting close' to raising EPS guidance
- 01/11/21
- Scotts Miracle-Gro CFO Randy Coleman departs
- 01/05/21
- Flowr, Hawthorne Canada announce completion of cannabis R&D facility
- 02/22/21
- Dish signs master lease agreement with SBA Communications
- 02/02/21
- PG&E unit sells rights to 700 towers to SBA Communications for $973M
- 01/24/21
- Fly Intel: Top five weekend stock stories
- 01/27/21
- Raymond James reports Q1 client assets under administration $1.02T
- 02/16/21
- Lone Pine bought Snap and Carvana during Q4, exited PayPal
- 12/28/20
- Insulet announces settlement of dispute with Ypsomed AG
- 09/21/20
- Insulet launches Omnipod DASH System in additional countries
- 02/16/21
- La-Z-Boy CEO Kurt Darrow to retire April 25
- 01/28/21
- La-Z-Boy increases quarterly dividend by 1c per share
- 01/11/21
- La-Z-Boy appoints Robert Sundy as chief commercial officer
- 12/10/20
- La-Z-Boy general counsel Stephen Krull to retire
- 12/22/20
- Leap Therapeutics announces publication of mechanism of action data for DKN-01
- 11/09/20
- Leap Therapeutics presents DKN-01 data at AACR conference
- 11/09/20
- Leap presents data from Phase 1b/2a clinical trial of DKN-01
- 09/24/20
- Leap Therapeutics granted FDA Fast Track Designation for DKN-01
- 02/17/21
- JLL appoints Gilda Perez-Alvarado as global CEO, Hotels & Hospitality
- 01/25/21
- JLL appoints Ingrid Jacobs as head of diversity, inclusion
- 11/24/20
- BP, Jones Lang LaSalle enter multi-year vested workplace evolution agreement
- 11/20/20
- JLL names Rastogi chief product officer to lead JLL Technologies
- 11/10/20
- Idexx Laboratories CFO sells 10K shares of common stock
- 03/01/21
- Hologic acquires Diagenode for $159M, sees accretion after FY22
- 02/15/21
- Fly Intel: Top five weekend stock stories
- 02/01/21
- Hologic, Google Cloud collaborate over digital diagnostic capabilities
- 01/08/21
- Hologic announces new, five-year $1B share repurchase plan
- 03/01/21
- Flexion announces FDA clearance for FX301 IND application
- 02/18/21
- Flexion to advance FX201 into high dose cohort of Phase 1 trial
- 02/01/21
- NBRPA, Sheryl Swoopes, Flexion partner to raise ZILRETTA awarness
- 01/13/21
- Flexion promotes Adam Muzikant to CBO
- 02/12/21
- DexCom CEO: Everything about G7 will be better than G6
- 02/11/21
- DexCom launches inaugural venture capital fund
- 01/14/21
- DexCom CEO sells 47K shares of common stock
- 10/14/20
- Casella Waste announces Shelley Sayward to assume General Counsel role
- 10/14/20
- Casella Waste announces permit expansion at North Country site
- 10/02/20
- Casella Waste acquires Pinto Trucking Services
- 03/01/21
- CACI gets prime spot on multiple-award contract for litigation support to DOJ
- 01/26/21
- CACI awarded $96M task order by U.S. Army
- 12/10/20
- Air Force awards CACI $160M task order to provide information technology support
- 10/22/20
- CACI awarded up to $86.5M, five-year DHS contract
- 01/28/21
- Broadridge begins development to be an approved SFT submitter
- 12/08/20
- Broadridge selected by BEC for updated Shareholder Rights Directive
- 11/09/20
- Broadridge names Edmund Reese as CFO, effective November 30
- 11/02/20
- LiquidX announces multi-year investment from Broadridge
- 01/27/21
- Avnet jumps over 5% to $39.69 after Q2 earnings beat, above-consensus Q3 view
- 11/23/20
- Avnet names Phil Gallagher CEO
- 01/21/21
- Apellis says 'on track' for Phase 3 GA results in 3Q21
- 12/10/20
- Swedish Orphan Biovitrum, Apellis report results from PEGASUS study
- 12/10/20
- Apellis and Sobi report top-line Phase 3 results of pegcetacoplan in PNH
- 12/07/20
- Apellis announces new analyses from Phase 3 PEGASUS study
- 02/01/21
- ADMA Biologics receives FDA approval for Biocenters facility in Knoxville
- 01/26/21
- ADMA Biologics receives unique permanent J-Code for Asceniv
- 01/19/21
- ADMA Biologics announces 2021 key strategic priorities
- 01/04/21
- ADMA receives temporary C-Code, pass-through payment status for ASCENIV
- 02/26/21 JPMorgan
- Jones Lang LaSalle price target raised to $200 from $176 at JPMorgan
- 01/25/21 Goldman Sachs
- Jones Lang LaSalle initiated with a Buy at Goldman Sachs
- 12/21/20 JPMorgan
- Jones Lang LaSalle price target raised to $172 from $132 at JPMorgan
- 10/07/20 Keefe Bruyette
- Jones Lang LaSalle downgraded to Market Perform at Keefe Bruyette
- 02/25/21 Oppenheimer
- Insulet price target raised to $277 from $235 at Oppenheimer
- 02/24/21 Raymond James
- Insulet price target raised to $296 from $282 at Raymond James
- 02/04/21 Piper Sandler
- Tandem trades at 'significant discount' to Insulet, says Piper Sandler
- 01/29/21 Piper Sandler
- Insulet downgraded to Neutral from Overweight at Piper Sandler
- 02/04/21 Truist
- Scotts Miracle-Gro price target raised to $270 from $250 at Truist
- 01/11/21 Raymond James
- Scotts Miracle-Gro price target raised to $274 from $224 at Raymond James
- 01/07/21 Truist
- Scotts Miracle-Gro price target raised to $250 from $180 at Truist
- 12/11/20
- Fly Intel: Top five analyst upgrades
- 02/17/21 Barclays
- Idexx Laboratories initiated with an Overweight at Barclays
- 01/29/21 JPMorgan
- Idexx Laboratories initiated with an Overweight at JPMorgan
- 08/17/20 Credit Suisse
- Idexx Laboratories price target raised to $422 from $415 at Credit Suisse
- 08/04/20 Credit Suisse
- Idexx Laboratories price target raised to $415 from $300 at Credit Suisse
- 01/29/21 Baird
- Apellis assumed at Outperform at Baird
- 12/14/20 Roth Capital
- Apellis price target raised to $73 from $50 at Roth Capital
- 12/10/20 Cowen
- Apellis price target raised to $55 from $45 at Cowen
- 12/04/20 JPMorgan
- Apellis price target raised to $87 from $50 at JPMorgan
- 02/23/21 Citi
- Citi opens long Arrow Electronics, short Avnet pair trade
- 01/29/21 Loop Capital
- Avnet price target raised to $39 from $32 at Loop Capital
- 01/19/21 Citi
- Citi boosts Avnet target to $40, opens 'Positive Catalyst Watch'
- 12/14/20 Goldman Sachs
- Avnet price target raised to $25 from $23 at Goldman Sachs
- 02/23/21 Credit Suisse
- SBA Communications price target lowered to $277 from $291 at Credit Suisse
- 02/23/21 Barclays
- SBA Communications price target raised to $310 from $305 at Barclays
- 02/23/21 Deutsche Bank
- SBA Communications price target lowered to $325 from $335 at Deutsche Bank
- 02/08/21 JPMorgan
- JPMorgan downgrades SBA to Neutral on 'lukewarm' tower stance
- 01/29/21 Baird
- Leap Therapeutics assumed at Outperform at Baird
- 06/29/20 Piper Sandler
- Leap Therapeutics initiated with an Overweight at Piper Sandler
- 01/29/21 Citi
- Citi opens 'Positive Catalyst Watch' on Raymond James, ups price target
- 01/15/21 Wells Fargo
- Raymond James double upgraded to Overweight at Wells Fargo
- 01/15/21 Wells Fargo
- Raymond James upgraded to Overweight from Underweight at Wells Fargo
- 01/05/21 Wolfe Research
- Raymond James upgraded to Outperform from Peer Perform at Wolfe Research
- 02/01/21 DA Davidson
- Weyerhaeuser price target raised to $34 from $29 at DA Davidson
- 12/04/20 Raymond James
- Weyerhaeuser upgraded to Outperform from Market Perform at Raymond James
- 08/03/20
- Fly Intel: Top five analyst downgrades
- 08/03/20 DA Davidson
- Weyerhaeuser downgraded to Neutral from Buy at DA Davidson
- 11/19/20 Raymond James
- La-Z-Boy price target raised to $46 from $37 at Raymond James
- 10/19/20 Sidoti
- La-Z-Boy upgraded to Buy from Neutral at Sidoti
- 06/25/20 Stifel
- La-Z-Boy price target raised to $37 from $25 at Stifel
- 04/13/20 Sidoti
- La-Z-Boy downgraded to Neutral from Buy at Sidoti
- 02/12/21 Oppenheimer
- DexCom price target raised to $449 from $415 at Oppenheimer
- 02/12/21 Citi
- DexCom price target lowered to $480 from $485 at Citi
- 02/12/21 Piper Sandler
- DexCom earnings selloff should be bought, says Piper Sandler
- 01/29/21 Piper Sandler
- DexCom price target raised to $500 from $465 at Piper Sandler
- 10/01/20 Raymond James
- ADMA Biologics price target raised to $9 from $7 at Raymond James
- 09/30/20 Jefferies
- ADMA Biologics shares 'in arbitrage territory,' says Jefferies
- 05/26/20 Maxim
- ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
- 05/07/20 Oppenheimer
- ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
- 02/16/21 B. Riley Securities
- CatchMark Timber price target raised to $12.50 from $11 at B. Riley
- 02/12/21 RBC Capital
- CatchMark Timber cut to Sector Perform at RBC Capital on more limited growth
- 02/12/21 RBC Capital
- CatchMark Timber downgraded to Sector Perform from Outperform at RBC Capital
- 10/30/20 RBC Capital
- CatchMark Timber upgraded to Outperform from Sector Perform at RBC Capital
- 02/23/21 William Blair
- William Blair reiterates Outperform on Leidos following quarterly results
- 01/29/21 Truist
- CACI price target raised to $290 from $275 at Truist
- 01/27/21 Stifel
- CACI 'very likely' to bid on Perspecta as well, says Stifel
- 09/22/20 JPMorgan
- JPMorgan upgrades 'relatively resilient' CACI to Overweight
- 02/03/21 BTIG
- Broadridge upgraded to Buy from Neutral at BTIG
- 12/18/20 Truist
- Broadridge initiated with a Buy at Truist
- 12/18/20 Truist
- Broadridge initiated with a Buy at Truist
- 08/17/20 JPMorgan
- Broadridge price target raised to $152 from $142 at JPMorgan
- 12/21/20
- Fly Intel: Top five analyst initiations
- 12/21/20 BofA
- Casella Waste initiated with a Neutral at BofA
- 10/15/20 Berenberg
- Casella Waste initiated with a Buy at Berenberg
- 09/24/20 Stifel
- Casella Waste upgraded to Buy at Stifel, in a position to sustain 7%-8% growth
- 08/20/20 Goldman Sachs
- Flexion initiated with a Neutral at Goldman Sachs
- 07/30/20 Oppenheimer
- Flexion initiated with an Outperform at Oppenheimer
- 07/29/20
- Fly Intel: Top five analyst initiations
- 07/29/20 Credit Suisse
- Flexion initiated with an Outperform at Credit Suisse
- 02/22/21 BTIG
- Hologic price target raised to $91 from $84 at BTIG
- 01/28/21 Wells Fargo
- Hologic price target raised to $95 from $90 at Wells Fargo
- 12/08/20 Argus
- Hologic price target raised to $100 from $85 at Argus
- 11/20/20
- Fly Intel: Top five analyst downgrades
- 02/12/21 Barclays
- ViaSat price target raised to $65 from $53 at Barclays
- 02/05/21 William Blair
- William Blair upgrades ViaSat, sees upside to $90-$110 per share
- 02/05/21 William Blair
- ViaSat upgraded to Outperform from Market Perform at William Blair
- 01/07/21 William Blair
- ViaSat win at Delta likely brings large upfront cost, says William Blair
- 01/29/21
- Weyerhaeuser reports Q4 ex-items EPS 48c, consensus 46c
- 10/30/20
- Weyerhaeuser reports Q3 ex-items EPS 52c, consensus 47c
- 02/04/21
- ViaSat reports Q3 non-GAAP EPS 39c, may not compare to consensus (1c)
- 11/05/20
- ViaSat reports Q2 adjusted EPS 31c, consensus (7c)
- 02/03/21
- Scotts Miracle-Gro sees 2021 adjusted EPS $8.00-$8.40, consensus $8.26
- 02/03/21
- Scotts Miracle-Gro reports Q1 adjusted EPS 39c, consensus (76c)
- 11/04/20
- Scotts Miracle-Gro sees FY21 sales growth 0%-5%, consensus $4.17B
- 11/04/20
- Scotts Miracle-Gro sees FY21 adj. EPS $8.00-$8.40, consensus $7.76
- 02/22/21
- SBA Communications sees FY21 AFFO $10-$10.41, consensus $10.12
- 02/22/21
- SBA Communications reports Q4 AFFO $2.49, consensus $2.44
- 11/02/20
- SBA Communications raises FY20 AFFO view to $9.27-$9.50 from $8.94-$9.33
- 11/02/20
- SBA Communications reports Q3 AFFO $2.38, consensus $2.32
- 01/27/21
- Raymond James reports Q1 adjusted EPS 2.24, consensus $1.72
- 02/23/21
- Insulet reports Q4 EPS (26c), consensus (4c)
- 11/04/20
- Insulet raises FY20 revenue growth guidance to 20%-21% from 17%-19%
- 11/04/20
- Insulet reports Q3 EPS 17c, consensus 8c
- 02/16/21
- La-Z-Boy sees Q4 revenue up 34%-39%, consensus $509.85M
- 02/16/21
- La-Z-Boy reports Q3 EPS 74c, consensus 70c
- 01/28/21
- La-Z-Boy sees Q3 consolidated sales down 1%-2% year-over-year
- 11/17/20
- La-Z-Boy sees Q3 revenue flat to up 4%, consensus $512M
- 11/12/20
- Leap Therapeutics reports Q3 EPS (9c), consensus (13c)
- 02/09/21
- Jones Lang LaSalle reports Q4 adjusted EPS $5.29 vs. $6.35 a year ago
- 02/09/21
- Jones Lang LaSalle reports Q4 adjusted EPS $5.29, consensus $3.93
- 11/02/20
- Jones Lang LaSalle reports Q3 adjusted EPS $2.99, consensus $1.25
- 11/02/20
- Jones Lang LaSalle reports Q3 adjusted EPS $2.99, consensus $1.25
- 02/02/21
- Idexx Laboratories sees FY21 EPS $7.39-$7.71, consensus $6.81
- 02/02/21
- Idexx Laboratories reports Q4 EPS $2.01 with items, consensus $1.40
- 10/29/20
- Idexx Laboratories reports Q3 EPS $1.69, consensus $1.43
- 01/27/21
- Hologic sees Q2 adjusted EPS $2.56-$2.68, consensus $2.02
- 01/27/21
- Hologic reports Q1 adjusted EPS $2.86, consensus $2.17
- 01/08/21
- Hologic reports preliminary Q1 revenue $1.61B, consensus $1.38B
- 01/13/21
- Flexion sees 2020 revenue $85.5M, consensus $84.88M
- 01/13/21
- Flexion sees Q4 revenue $26.3M, consensus $25.66M
- 11/04/20
- Flexion reports Q3 EPS (50c), consensus (51c)
- 02/11/21
- DexCom sees FY21 revenue $2.21B-$2.31B, consensus $2.33B
- 02/11/21
- DexCom reports Q4 EPS $3.48, consensus 92c
- 01/11/21
- DexCom sees FY20 revenue $1.93B, consensus $1.91B
- 01/11/21
- DexCom reports preliminary Q4 revenue at least $567M, consensus $550.73M
- 02/18/21
- Casella Waste sees FY21 revenue $815M-$830M, consensus $832.21M
- 02/18/21
- Casella Waste reports Q4 adjusted EPS 17c, consensus 14c
- 10/29/20
- Casella Waste raises FY20 revenue view to $760M-$775M from $755M-$770M
- 10/29/20
- Casella Waste reports Q3 EPS 31c, consensus 29c
- 02/11/21
- CatchMark Timber reports Q4 EPS (6c), consensus (4c)
- 10/29/20
- CatchMark Timber reports Q3 EPS (9c), consensus (8c)
- 01/27/21
- CACI sees FY21 EPS $14.47-$15.25, consensus $15.01
- 01/27/21
- CACI reports Q2 EPS $4.18, consensus $3.60
- 10/28/20
- CACI raises FY21 EPS view to $14.47-$15.25 from $13.50-$14.28
- 10/28/20
- CACI reports Q1 EPS $3.67, consensus $3.11
- 02/02/21
- Broadridge reports Q2 adjusted EPS 73c, consensus 70c
- 12/10/20
- Broadridge backs FY21 adjusted EPS growth of 6%-10%, consensus $5.50
- 12/10/20
- Broadridge targets adjusted EPS growth FY20-FY23 of 8%-12%
- 10/30/20
- Broadridge reports Q1 adjusted EPS 98c, consensus 63c
- 01/27/21
- Avnet sees Q3 adjusted EPS 52c-58c, consensus 48c
- 01/27/21
- Avnet reports Q2 adjusted EPS 48c, consensus 39c
- 01/27/21
- Notable companies reporting after market close
- 10/28/20
- Avnet sees Q2 EPS 33c-43c, consensus 34c
- 02/25/21
- Apellis reports Q EPS 93c, consensus (75c)
- 11/02/20
- Apellis reports Q3 EPS ($1.79), consensus ($1.58)
- 01/19/21
- ADMA Biologics sees FY20 revenue $42.2M, consensus $40.33M
- 01/19/21
- ADMA Biologics sees Q4 revenue $13.9M, consensus $12.05M
|